<p>目前在 <strong>ARK Invest</strong> 内部展开的大规模轮换表明，<strong>Cathie Wood</strong> 认为 2026 年将是基因组革命的决定性亮相。</p>
<ul>
<li><strong>PACB 股票上涨。 查看图表和价格走势。</strong></li>
</ul>
<p>随着 2025 年的结束，ARK 积极削减 特斯拉公司 (NASDAQ: TSLA) 和 <strong>Rocket Lab Corp.</strong> (NASDAQ: RKLB) 等传统赢家，以资助对基因编辑先驱的数百万美元的增持。</p>
<p><strong>下一步阅读：</strong> Palantir：从 Meme 股票到 2025 年的市场领导者</p>
<p>ARK Invest 特别增持了 <strong>CRISPR Therapeutics AG</strong> (NASDAQ: CRSP)、<strong>Intellia Therapeutics, Inc.</strong> (NASDAQ: NTLA)、<strong>Beam Therapeutics, Inc.</strong> (NASDAQ: BEAM) 和 <strong>Pacific Biosciences of California Inc.</strong> (NASDAQ: PACB)，以迎接年底的到来。</p>
<h2><strong>策略</strong></h2>
<p>Wood 的理论建立在人工智能与可编程生物学的结合之上。今年早些时候，Wood 强调了人工智能在医疗保健中的变革潜力，称其为人工智能的 最深远应用。</p>
<p>根据 Ark 的多组学飞轮 框架，人工智能加速了多组学的各个方面，从生成生物数据到诊断疾病和开发新药。</p>
<p>“更智能的算法使基因测序更快；更便宜的测序为人工智能提供了更多学习数据；基因编辑的突破可以为新疗法打开大门，” Wood 解释道。</p>
<h2><strong>持股</strong></h2>
<p>到 2025 年底，ARK 将 CRISPR Therapeutics 的权重提高到其旗舰 <strong>ARKK 创新基金</strong> (BATS: ARKK) 的 5% 以上，Beam Therapeutics 增长到 ARKK 的 3.41%，Twist 占 2%，Intellia 占同一基金的 1.14%。</p>
<p>Ark Invest 还拥有 <strong>Ark Genomic Revolution Fund</strong> (BATS: ARKG)，专注于投资与基因组革命主题相关的各个行业的公司，包括医疗保健和信息技术。</p>
<p><strong>下一步阅读：</strong></p>
<ul>
<li>金属表现如 Meme 股票——关于重大白银保证金追缴的未确认传闻</li>
</ul>
<p><em>照片来源：Shutterstock</em></p>

CRISPR治疗

<p>Cathie Wood 的 ARK Invest 正在转向基因组股票，预计到 2026 年将迎来重大的基因组革命。该公司已经出售了特斯拉等传统股票，重金投资于基因编辑公司，如 CRISPR Therapeutics、Beam Therapeutics 和 Pacific Biosciences。Wood 强调了人工智能与生物学之间的协同作用，预测人工智能的进步将提升基因测序和药物开发的效率。到 2025 年底，ARK 在这些公司的持股将在其旗舰 ARKK 创新基金和 Ark 基因组革命基金中显著增加</p>

<p>The massive rotation currently unfolding within <strong>ARK Invest</strong> suggests that <strong>Cathie Wood</strong> thinks 2026 will be the definitive coming-out party for the genomic revolution.</p>
<div class="lb-trans"><p>目前在 <strong>ARK Invest</strong> 内部展开的大规模轮换表明，<strong>Cathie Wood</strong> 认为 2026 年将是基因组革命的决定性亮相。</p>
</div><ul>
<li><strong>PACB stock is up. See the chart and price action here.</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>PACB 股票上涨。 查看图表和价格走势。</strong></li>
</ul>
</div><p>As 2025 draws to a close, ARK aggressively trimmed legacy winners such as <strong>Tesla, Inc.</strong> (NASDAQ: TSLA) and <strong>Rocket Lab Corp.</strong> (NASDAQ: RKLB) to fund a multi-million dollar accumulation of gene-editing pioneers.</p>
<div class="lb-trans"><p>随着 2025 年的结束，ARK 积极削减 特斯拉公司 (NASDAQ: TSLA) 和 <strong>Rocket Lab Corp.</strong> (NASDAQ: RKLB) 等传统赢家，以资助对基因编辑先驱的数百万美元的增持。</p>
</div><p><strong>Read Next:</strong> Palantir: From Meme Stock To Market Leader In 2025</p>
<div class="lb-trans"><p><strong>下一步阅读：</strong> Palantir：从 Meme 股票到 2025 年的市场领导者</p>
</div><p>ARK Invest has been specifically loading up on shares of <strong>CRISPR Therapeutics AG</strong> (NASDAQ: CRSP), <strong>Intellia Therapeutics, Inc.</strong> (NASDAQ: NTLA), <strong>Beam Therapeutics, Inc.</strong> (NASDAQ: BEAM) and <strong>Pacific Biosciences of California Inc.</strong> (NASDAQ: PACB) heading into the end of the year.</p>
<div class="lb-trans"><p>ARK Invest 特别增持了 <strong>CRISPR Therapeutics AG</strong> (NASDAQ: CRSP)、<strong>Intellia Therapeutics, Inc.</strong> (NASDAQ: NTLA)、<strong>Beam Therapeutics, Inc.</strong> (NASDAQ: BEAM) 和 <strong>Pacific Biosciences of California Inc.</strong> (NASDAQ: PACB)，以迎接年底的到来。</p>
</div><h2><strong>The Strategy</strong></h2>
<div class="lb-trans"><h2><strong>策略</strong></h2>
</div><p>Wood's thesis is built on the combination of artificial intelligence and programmable biology. Earlier this year, Wood highlighted the transformative potential of AI in health care, calling it the most profound application of artificial intelligence.</p>
<div class="lb-trans"><p>Wood 的理论建立在人工智能与可编程生物学的结合之上。今年早些时候，Wood 强调了人工智能在医疗保健中的变革潜力，称其为人工智能的 最深远应用。</p>
</div><p>According to Ark’s multiomics flywheel framework, AI accelerated all aspects of multiomics from generating biological data to diagnosing diseases and developing new drugs.</p>
<div class="lb-trans"><p>根据 Ark 的多组学飞轮 框架，人工智能加速了多组学的各个方面，从生成生物数据到诊断疾病和开发新药。</p>
</div><p>“Smarter algorithms make gene sequencing faster; cheaper sequencing gives AI more data to learn from; and breakthroughs in gene editing can open the door to new treatments,” Wood explained.</p>
<div class="lb-trans"><p>“更智能的算法使基因测序更快；更便宜的测序为人工智能提供了更多学习数据；基因编辑的突破可以为新疗法打开大门，” Wood 解释道。</p>
</div><h2><strong>The Holdings</strong></h2>
<div class="lb-trans"><h2><strong>持股</strong></h2>
</div><p>By late December 2025, ARK increased its weight in CRISPR Therapeutics to over 5% of its flagship <strong>ARKK Innovation Fund</strong> (BATS: ARKK), Beam Therapeutics grew to 3.41% of ARKK, Twist accounted for 2% and Intellia was 1.14% of the same fund.</p>
<div class="lb-trans"><p>到 2025 年底，ARK 将 CRISPR Therapeutics 的权重提高到其旗舰 <strong>ARKK 创新基金</strong> (BATS: ARKK) 的 5% 以上，Beam Therapeutics 增长到 ARKK 的 3.41%，Twist 占 2%，Intellia 占同一基金的 1.14%。</p>
</div><p>Ark Invest also has the <strong>Ark Genomic Revolution Fund</strong> (BATS: ARKG) dedicated to investing in companies across sectors, including health care and information technology, that are relevant to the theme of the genomics revolution.</p>
<div class="lb-trans"><p>Ark Invest 还拥有 <strong>Ark Genomic Revolution Fund</strong> (BATS: ARKG)，专注于投资与基因组革命主题相关的各个行业的公司，包括医疗保健和信息技术。</p>
</div><p><strong>Read Next:</strong></p>
<div class="lb-trans"><p><strong>下一步阅读：</strong></p>
</div><ul>
<li>Metals Acting Like Meme Stocks—Unconfirmed Rumor Of Major Silver Margin Call</li>
</ul>
<div class="lb-trans"><ul>
<li>金属表现如 Meme 股票——关于重大白银保证金追缴的未确认传闻</li>
</ul>
</div><p><em>Photo: Shutterstock</em></p>
<div class="lb-trans"><p><em>照片来源：Shutterstock</em></p>
</div>

Cathie Wood 的生物技术趋势：Twist, Beam, CRISPR 最新的股票选择